Overview

A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This proof of concept study will be a placebo controlled, randomised, double blind, parallel study. The purpose of the study is to determine efficacy for AKR 202 in the treatment of osteoarthritis (OA) pain in the knee.
Phase:
Phase 2
Details
Lead Sponsor:
Akron Molecules AG